We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Sensitive Urine Assay Detects Prostate Cancer

By LabMedica International staff writers
Posted on 29 Aug 2011
An innovative prostate screening test has been developed that may be more sensitive in detecting prostate cancer than traditional screening methods. More...


The test provides an original way to look at prostate cancer diagnosis utilizing a novel biological assay, which differentiates prostate-specific antigen's (PSA) molecular structures arising from cancer versus noncancerous glands.

Scientists at Case Western Reserve University School of Medicine collaborating with other institutions, studied a urine-based test that works differently than most prostate screening methods. They used a novel assay to separate PSA protein structures as being linked to either a “cancer” or “noncancer” pathologic diagnosis based on ultrasound-guided biopsy. Instead of attempting to find a single genetic biomarker, which predicts the presence of cancer, the Prostate-specific Antigen/Solvent Interaction Analysis (PSA/SIA) assay is based on the assumption that there may be myriad different ultrastructural changes in the PSA protein, which define the cancer phenotype.

The PSA/SIA assay determined the relative partitioning of heterogeneous PSA isoform populations in urine between two aqueous phases. The initial study, collected at three clinical sites, followed 222 men, and found that the new screening method had 100% sensitivity with no false negative results and 80.3% specificity showing low false positive results. The accuracy of traditional serum PSA is limited by both relatively high false positive and false negative rates. Current diagnostic strategies that use total PSA to determine the need for biopsy demonstrate false positive rates of approximately 55% to 75%.

The PSA/SIA assay, a product of AnalizaDx (Cleveland, OH, USA) provides ratiometric information independently of PSA concentration. In the preliminary study, analysis of the overall structurally heterogeneous PSA isoform population using the SIA assay showed promising results to be further evaluated in future studies. Arnon Chait, PhD, CEO of AnalizaDx, said, "This new assay is a complete departure from how the scientific community has looked at biomarkers for cancer. Instead of just measuring levels of proteins, we are exploring changes in structure which are associated with cancer.” The study was published online on July 22, 2011, in the journal Urology.

Related Links:
Case Western Reserve University School of Medicine
AnalizaDx




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gastrointestinal Panel
Xpert® GI Panel
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Graphical Abstract (Zeyang Shen et al., Shotgun Metagenomics Reveals Skin Microbiome Composition and Function in Infant Atopic Disease, Allergy, 2026. DOI: 10.1111/all.70449)

Infant Skin Microbiome Show Links to Later Eczema and Food Allergies

Eczema, or atopic dermatitis, and food allergies often begin in infancy and are among the earliest stages of the atopic march. Atopic dermatitis alone can affect up to 20% of children, yet objective indicators... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: Under the theme “From Tissue to Answer”, the launch of VisiOmics anchors a comprehensive pathology portfolio spanning tissue and molecular pathology (Photo courtesy of MGI Tech Co., Ltd.)

MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026

MGI Tech Co., Ltd. (Shenzhen, China) introduced VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence staining and imaging system, at the 38th European Congress of Pathology (ECP 2026)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.